Search Results - norris+lam

2 Results

Sort By:

Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)

Abstract: Immortalization of plasma cells leads to plasma cell malignancy diseases such as multiple myeloma (MM). B-cell maturation antigen (BCMA) is a protein that is preferentially expressed by malignant and normal B cells and plasma cells, butnot on other cells in the body. This limited expression profile suggests that BCMA is a promising target...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Norris Lam, Benjamin Buelow

Keywords(s): act, adoptive cell therapy, B-cell Malignancies, B-cell Maturation Antigen, BCMA, BIOLOGIC, CANCER, CAR, chimeric antigen receptor, Hodgkin Lymphoma, Hodgkin’s Lymphoma, Kochenderfer, Mm, MULTIPLE MYELOMA, Non-Hodgkin Lymphoma, Non-Hodgkin’s Lymphoma, Plasma Cell Malignancies

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20

Abstract: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Norris Lam

Keywords(s): act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Oncology